Content area
Full text
An advisory committee of the Food and Drug Administration voted by 8-7 last week to require drug companies to display a "black box" warning label on several stimulant drugs used to treat attention-deficit/hyperactivity disorder.
The drugs are methylphenidate hydrochloride (sold as Ritalin and Concerta) and the amphetamine formulation sold in the United States as Adderall.
The committee, whose recommendation was unexpected, said the warning was necessary because of the drugs' association with rises in blood pressure and heart rate, which have...